期刊文献+

Opioid/naloxone prolonged release combinations for opioid induced constipation 被引量:4

Opioid/naloxone prolonged release combinations for opioid induced constipation
下载PDF
导出
摘要 I read with great interest the recent article by Chen et al in a recent issue of your esteemed journal.The article is highly thought provoking.One emerging therapeutic alternative for opioid induced constipation is the emergence of opioid/naloxone prolonged release combinations.For instance,naloxone when administered in a 1:2 ratio with oxycodone reverses the inhibitory effect of oxycodone on the gastrointestinal tract.The advantage of oxycodone/naloxone prolonged release(OXN) is that while its anti-nociceptive efficacy is equivalent to that of oxycodone prolonged release(OXC),it significantly decreases the "Bowel Function Index" thereby ameliorating symptoms of opioid induced constipation to a large extent.Schutter et al in a recent study have reported a decrease in the bowel function index from 38.2 to 15.1.Similarly,L wenstein et al in another recent study have reported that following a month of therapy,complete spontaneous bowel movements per week is increased from one in OXC therapy to three in OXN therapy. I read with great interest the recent article by Chen et al in a recent issue of your esteemed journal.The article is highly thought provoking.One emerging therapeutic alternative for opioid induced constipation is the emergence of opioid/naloxone prolonged release combinations.For instance,naloxone when administered in a 1:2 ratio with oxycodone reverses the inhibitory effect of oxycodone on the gastrointestinal tract.The advantage of oxycodone/naloxone prolonged release(OXN) is that while its anti-nociceptive efficacy is equivalent to that of oxycodone prolonged release(OXC),it significantly decreases the "Bowel Function Index" thereby ameliorating symptoms of opioid induced constipation to a large extent.Schutter et al in a recent study have reported a decrease in the bowel function index from 38.2 to 15.1.Similarly,L wenstein et al in another recent study have reported that following a month of therapy,complete spontaneous bowel movements per week is increased from one in OXC therapy to three in OXN therapy.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第29期3921-3922,共2页 世界胃肠病学杂志(英文版)
关键词 Opiod naloxone Cancer Morphine Carcinogenesis 纳络酮 药物 便秘 缓释 肠道功能 阿片样物质 纳洛酮 抑制作用
  • 相关文献

参考文献1

二级参考文献38

  • 1Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011; 106: 835-842; quiz 843. 被引量:1
  • 2Holzer P. New approaches to the treatment of opioid-in- duced constipation. Eur Rev Med Pharmacol Sci 2008; 12 Suppl1: 119-127. 被引量:1
  • 3Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009; 155: 11-17. 被引量:1
  • 4Hanauer SB. The role of loperamide in gastrointestinal disor- ders. Rev Gastroenterol Disord 2008; 8: 15-20. 被引量:1
  • 5Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999; 13 Suppl A: 71A-75A. 被引量:1
  • 6Baker DE. Loperamide: a pharmacological review. Rev Gas- troenterol Disord 2007; 7 Suppl 3: S11-S18. 被引量:1
  • 7Nozaki-Taguchi N,Yaksh TL. Characterization of the anti-hyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide. Anesthesiology 1999; 90: 225-234. 被引量:1
  • 8Tagaya E,Tamaoki J,Chiyotani A,Konno K. Stimulation of opioid mu-receptors potentiates beta adrenoceptor-mediated relaxation of canine airway smooth muscle. J Pharmacol Exp Ther 1995; 275: 1288-1292. 被引量:1
  • 9Ozdem SS,Batu O,Tayfun F,Yalcin O,Meiselman HJ,Bas- kurt OK. The effect of morphine in rat small mesenteric arter- ies. Vascul Pharmacol 2005; 43: 56-61. 被引量:1
  • 10Raimundo JM,Sudo RT,Pontes LB,Antunes F,Trachez MM, Zapata-Sudo G. In vitro and in vivo vasodilator activity of racemic tramadol and its enantiomers in Wistar rats. Eur J Pharmacol 2006; 530: 117-123. 被引量:1

共引文献19

同被引文献22

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部